In this report, we provide the first evidence that DARPP-32 overexpression in EGFR-mutated LUAD promotes ERBB3-mediated oncogenic signaling to drive EGFR TKI therapy-refractory cancer progression. This evidence concerns the gene EGFR and cancer.